Mavoglurant(Mavoglurant) - 药物靶点：mGluR5_在研适应症：物质滥用，戒酒，酒精使用障碍_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

mGluR5

作用机制

mGluR5拮抗剂(代谢型谷氨酸受体-5拮抗剂)

治疗领域

其他疾病肿瘤神经系统疾病

在研适应症

物质滥用戒酒酒精使用障碍+ [4]

非在研适应症

药物性运动障碍运动失调脆性X综合征+ [7]

原研机构

Novartis Pharma AG

在研机构

Stalicla SA初创企业

National Institute on Alcohol Abuse & Alcoholism

National Institute on Drug Abuse

非在研机构

Novartis Pharmaceuticals Canada, Inc.

Novartis Pharmaceuticals Corp.

Novartis AG

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (欧盟)

登录后查看时间轴

结构

分子式C19H23NO3

InChIKeyZFPZEYHRWGMJCV-ZHALLVOQSA-N

CAS号543906-09-8

关联

32

项与 Mavoglurant 相关的临床试验

NCT06136195 / Recruiting临床2期IIT

Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers

The purpose of this research study is to find out about the effects of a drug called mavoglurant on alcohol consumption.

开始日期2024-07-01

申办/合作机构

Yale University

[+1]

NCT05203965 / Recruiting早期临床1期IIT

Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant

The purpose of this study is to evaluate the role of Mavoglurant in clarifying the neurobiology of alcoholism risk. This is a one-site, randomized, within subjects, counterbalanced double-blind study of a single dose (200mg) of Mavoglurant and placebo.

开始日期2022-05-17

申办/合作机构

Yale University

NCT04771143 / Withdrawn临床1期

A Randomized, Participant- and Investigator-blinded, Placebo-controlled, Parallel Group Study to Assess Safety, Tolerability, and Potential Interactions of Oral AFQ056 Given Concurrently With Cocaine

This is a study to assess safety, tolerability and interactions of AFQ056 and cocaine in patients with cocaine use disorder.

开始日期2021-07-21

申办/合作机构

Novartis Pharmaceuticals Canada, Inc.

[+1]

100 项与 Mavoglurant 相关的临床结果

登录后查看更多信息

100 项与 Mavoglurant 相关的转化医学

登录后查看更多信息

100 项与 Mavoglurant 相关的专利（医药）

登录后查看更多信息

61

项与 Mavoglurant 相关的文献（医药）

2024-11-01·Psychopharmacology

The mGlu5 receptor negative allosteric modulator mavoglurant reduces escalated cocaine self-administration in male and female rats

Article

作者: Whiting, Kimberly E ; Volkow, Nora D ; Vendruscolo, Janaina C M ; Vendruscolo, Leandro F ; Acri, Jane B ; Koob, George F

AbstractRationaleCocaine use disorder (CUD) is a brain disorder for which there is no Food and Drug Administration-approved pharmacological treatment. Evidence suggests that glutamate and metabotropic glutamate receptor subtype 5 (mGlu5) play critical roles in synaptic plasticity, neuronal development, and psychiatric disorders.ObjectiveIn the present study, we tested the hypothesis that the mGlu5 receptor is functionally involved in intravenous cocaine self-administration and assessed the effects of sex and cocaine exposure history.MethodsWe used a preclinical model of CUD in rats that were allowed long access (LgA; 6 h/day) or short access (ShA; 1 h/day) to intravenous cocaine (750 µg/kg/infusion [0.1 ml]) self-administration. Rats received acute intraperitoneal or oral administration of the mGlu5 receptor negative allosteric modulator mavoglurant (1, 3, and 10 mg/kg) or vehicle.ResultsBoth intraperitoneal and oral mavoglurant administration dose-dependently reduced intravenous cocaine self-administration in the first hour and in the entire 6 h session in rats in the LgA group, with no effect on locomotion. In the ShA group, mavoglurant decreased locomotion but had no effects on cocaine self-administration. We did not observe significant sex × treatment interactions.ConclusionsThese findings suggest that the mGlu5 receptor is involved in escalated cocaine self-administration. These findings support the development of clinical trials of mavoglurant to evaluate its potential therapeutic benefits for CUD.

2024-03-01·Journal of Clinical Investigation

Effects of AFQ056 on language learning in fragile X syndrome

Article

作者: Kaufmann, Walter E ; Long, Jeff ; Klingner, Elizabeth ; Cudkowicz, Merit ; Huff, Trevis ; McDuffie, Andrea ; Erickson, Craig A ; Costigan, Michele ; Friedmann, Katherine ; Berry-Kravis, Elizabeth ; Moshinsky, Michael ; Fedler, Janel ; Harkey, Brittney ; Hagerman, Randi ; Tassone, Flora ; Hoffmann, Anne ; Pearson, Brenda ; Ecklund, Dixie ; Veenstra-VanderWeele, Jeremy ; Bullard, Lauren ; Staley, Kevin ; Coffey, Christopher S ; Klements, David ; Hessl, David ; Ethridge, Lauren ; Abbeduto, Leonard

BACKGROUNDFXLEARN, the first-ever large multisite trial of effects of disease-targeted pharmacotherapy on learning, was designed to explore a paradigm for measuring effects of mechanism-targeted treatment in fragile X syndrome (FXS). In FXLEARN, the effects of metabotropic glutamate receptor type 5 (mGluR5) negative allosteric modulator (NAM) AFQ056 on language learning were evaluated in 3- to 6-year-old children with FXS, expected to have more learning plasticity than adults, for whom prior trials of mGluR5 NAMs have failed.METHODSAfter a 4-month single-blind placebo lead-in, participants were randomized 1:1 to AFQ056 or placebo, with 2 months of dose optimization to the maximum tolerated dose, then 6 months of treatment during which a language-learning intervention was implemented for both groups. The primary outcome was a centrally scored videotaped communication measure, the Weighted Communication Scale (WCS). Secondary outcomes were objective performance-based and parent-reported cognitive and language measures.RESULTSFXLEARN enrolled 110 participants, randomized 99, and had 91 who completed the placebo-controlled period. Although both groups made language progress and there were no safety issues, the change in WCS score during the placebo-controlled period was not significantly different between the AFQ056 and placebo-treated groups, nor were there any significant between-group differences in change in any secondary measures.CONCLUSIONDespite the large body of evidence supporting use of mGluR5 NAMs in animal models of FXS, this study suggests that this mechanism of action does not translate into benefit for the human FXS population and that better strategies are needed to determine which mechanisms will translate from preclinical models to humans in genetic neurodevelopmental disorders.TRIAL REGISTRATIONClincalTrials.gov NCT02920892.FUNDING SOURCESNeuroNEXT network NIH grants U01NS096767, U24NS107200, U24NS107209, U01NS077323, U24NS107183, U24NS107168, U24NS107128, U24NS107199, U24NS107198, U24NS107166, U10NS077368, U01NS077366, U24NS107205, U01NS077179, and U01NS077352; NIH grant P50HD103526; and Novartis IIT grant AFQ056X2201T for provision of AFQ056.

2024-02-01·Heliyon

Constrained numerical deconvolution using orthogonal polynomials

Article

作者: Maestre, J M ; Aarons, L ; Chanfreut, P

In this article, we present an enhanced version of Cutler's deconvolution method to address the limitations of the original algorithm in estimating realistic input and output parameters. Cutler's method, based on orthogonal polynomials, suffers from unconstrained solutions, leading to the lack of realism in the deconvolved signals in some applications. Our proposed approach incorporates constraints using a ridge factor and Lagrangian multipliers in an iterative fashion, maintaining Cutler's iterative projection-based nature. This extension avoids the need for external optimization solvers, making it particularly suitable for applications requiring constraints on inputs and outputs. We demonstrate the effectiveness of the proposed method through two practical applications: the estimation of COVID-19 curves and the study of mavoglurant, an experimental drug. Our results show that the extended method presents a sum of squared residuals in the same order of magnitude of that of the original Cutler's method and other widely known unconstrained deconvolution techniques, but obtains instead physically plausible solutions, correcting the errors introduced by the alternative methods considered, as illustrated in our case studies.

12

项与 Mavoglurant 相关的新闻（医药）

2024-09-19

·GlobeNewswire-Health Care

Dr. Paulo Fontoura, MD, PhD, joins STALICLA as Chief Scientific and Clinical Development Advisor

Press Release Dr. Paulo Fontoura, MD, PhD, joins STALICLA as Chief Scientific and Clinical Development Advisor Geneva, Switzerland – September 19, 2024 – STALICLA SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for neurodevelopmental disorders, announced today that Dr. Paulo Fontoura will be joining their drug development team as Chief Scientific and Clinical Development Advisor. Dr. Fontoura will work to support STALICLA’s mission to transform the treatment landscape for neurodevelopmental disorders. Lynn Durham, CEO of STALICLA, said: “We are delighted and humbled to welcome Paulo to the STALICLA team. With his unparalleled insight and unique understanding of CNS drug development and neurodevelopmental disorders, he is strengthening STALICLA’s position as a pioneer in precision neuropsychiatry. Paulo’s expertise will be instrumental in helping us achieve our next milestones, notably our entry into two Phase 2 clinical trials in subgroups of patients with autism spectrum disorder (ASD), each with expected readouts in the coming 24 months.” Dr. Paulo Fontoura is a pioneer in innovative clinical development strategies. During his 16-year tenure at Roche, he served as the Global Head of Neuroscience Clinical Development; he was instrumental in the launch of several groundbreaking medications targeting neurological conditions, including Multiple Sclerosis (MS), Spinal Muscular Atrophy (SMA), and Neuromyelitis Optica Spectrum Disorder (NMOSD), as well as pioneering work on Alzheimer's, Parkinson's, Huntington's disease, and several psychiatric and neurodevelopmental disorders. Specifically, he and his team spearheaded the clinical development of new therapies for Fragile X, Down's and Angelman's syndromes, and the first pharmacological treatment for core symptoms of ASD which reached Phase 3 clinical trials in both adults and children. Additionally, his team co-led the Autism Innovative Medicine Studies (AIMS) including EU-AIMS and AIMS-2-TRIALS public private partnership. Dr. Fontoura has also had an illustrious academic career. He held multiple faculty positions at the New University of Lisbon and Stanford University, where he earned his MD and a PhD in Neuroimmunology and trained as a clinical neurologist. In recognition of his exceptional achievements in the field of neuroscience, he was elected as a Fellow of the American Academy of Neurology in 2022. He currently serves as a visiting professor at the New University of Lisbon and lectures at the European Center of Pharmaceutical Medicine in Basel. Paulo Fontoura MD, PhD, Chief Scientific and Clinical Development Advisor, said: “I am thrilled to join the STALICLA team and help them develop therapies for people with neurodevelopmental disorders. Their approach promises to bring real breakthroughs in this area of great medical need.” About STALICLA: STALICLA SA is a Swiss clinical-stage biopharmaceutical company, revolutionizing the treatment of neurodevelopmental disorders. The company has developed a clinically validated neuro precision development platform, successfully delivering stratified patient subgroups and advancing tailored treatment options. Its lead NDD asset, STP1, and a second NDD asset are set to enter Phase 2 trials with expected readouts within 24 months. STP7 (Mavoglurant), is also being advanced for Phase 3 trials, fully funded by the US government. For more information, please visit: www.stalicla.com. Contacts: STALICLA SALynn Durham Founder & Chief Executive Officerlynn.durham@stalicla.com Media & InvestorsChris MaggosCohesion Bureauchris.maggos@cohesionbureau.com+41 79 367 6254 Attachment 20240918 Paulo Fontoura PR_final

临床2期临床3期高管变更

2024-06-28

·GlobeNewswire-Health Care

STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines

STALICLA’s precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined subgroup of patients with autism and numerical improvement in core symptoms June 27, 2024 – STALICLA SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for neuropsychiatric and neurodevelopmental disorders, today announced the publication of a landmark phase 1b study with STP1, a novel combination therapy tailored for the treatment of a clinically and biologically defined subgroup of patients with autism spectrum disorder (ASD), named ASD Phenotype 1 (ASD-Phen1). The results of the study were published in the peer-reviewed journal Biomedicines, in an article titled “Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD”. Lynn Durham, CEO of STALICLA, highlighted: “This study marks a significant milestone in the advancement of precision medicine for ASD. It is a first-of-its-kind stratification-based approach for clinical development in neurodevelopmental disorders, demonstrating the potential of precision medicine in ASD.” The randomized, double-blind, placebo-controlled phase 1b clinical trial evaluated the safety and tolerability of STP1, a combination of ibudilast and bumetanide, in ASD-Phen1 patients. The clinical trial (registered at clinicaltrials.gov NCT04644003), involved two 14-day treatment phases of ASD-Phen1 patients receiving STP1 or placebo. The results showed that STP1 was well-tolerated with no significant adverse effects reported. Significant and dose-related reductions in gamma power were observed in the whole brains of patients taking STP1, particularly in regions associated with executive function and memory. Additionally, STP1 increased alpha 2 power in frontal and occipital regions, while improving habituation and neural synchronization to auditory chirps. Dr. Craig A. Erickson, Associate Professor, UC Department of Psychiatry and Behavioral Neuroscience, Cincinnati Children’s Hospital Medical Center, and the principal investigator of the study, remarked: “The electrophysiological signals from this study are remarkable and represent the strongest early trial target engagement signals our lab has seen in the autism field.” Dr. Laura Pérez-Cano, Head of Discovery at STALICLA and co-author of the study, added: “These findings not only highlight the potential of STP1 as a therapeutic option for ASD-Phen1 patients but also underscore the importance of combining biologically-based patient stratification with quantifiable outcome measures such as EEG that can then be correlated with behavioral measures.” By focusing on a biologically defined subgroup of ASD patients, STALICLA is moving closer to making personalized treatment options a reality for patients with ASD. This approach has the potential to revolutionize the treatment of ASD and other neuropsychiatric conditions. STALICLA is a global, clinical-stage biotechnology company focused on advancing precision medicine for brain disorders. The company has developed a unique neuro precision development platform, DEPI, supported by clinical validation in a first indication: Autism Spectrum Disorder. Its lead neurodevelopmental disorder asset, STP1, is entering Phase 2 trials. Its lead neuropsychiatry asset, STP7 (Mavoglurant), fully funded by the US government, will soon be Phase 3 ready for Cocaine Use Disorder. ‎ The content above comes from the network. if any infringement, please contact us to modify.

临床结果

2024-05-08

·GlobeNewswire-Health Care

STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant) to treat cocaine use disorder

May 2, 2024 – STALICLA SA, a late-stage biotechnology company specializing in precision medicine for brain disorders, announces the First Patient First Visit (FPFV) for the company's drug-drug interaction (DDI) study of STP7 (Mavoglurant), an mGluR5 negative allosteric modulator, licensed to STALICLA by Novartis. The DDI study is the last regulatory requirement in a comprehensive Phase 2 program and completion is expected to trigger initiation of a Phase 3 study in the U.S. in 2025. Lynn Durham, CEO and Founder of STALICLA said, “This DDI study unlocks the opportunity under our Cooperative Research and Development Agreement with the U.S. NIH National Institute of Drug Abuse (NIDA) to begin Phase 3 trials for STP7 in 2025 to address the high unmet medical need of cocaine abuse globally. Results from successfully completed Phase 2 studies for cocaine use disorder (CUD) showed highly convincing and unprecedented efficacy results including increase in abstinence from cocaine use and reduction in co-morbid dependencies such as alcohol abuse with STP7 (Mavoglurant). In addition, STALICLA is investigating alternative therapeutic indications for STP7 (Mavoglurant) to benefit patients with other CNS conditions.” STP7 (Mavoglurant) is the most clinically advanced negative allosteric modulator of the glutamate receptor 5 (mGluR5 NAM). As well as its role in addiction pathophysiology, mGluR5 has been implicated in mood disorders and neurodevelopmental disorders such as Fragile X and autism spectrum disorder. Comprehensive clinical studies by Novartis of STP7 (Mavoglurant) to date have included over 1800 adults for up to 2 years, demonstrating good safety and tolerability and significant reduction in cocaine use and positioning STP7 (Mavoglurant) as a strong candidate therapy for substance use and other CNS disorders. STALICLA SA is a Swiss clinical-stage biopharmaceutical company, pioneering precision treatment in neurodevelopmental and neuropsychiatric disorders. Its AI-driven precision neuro medicine platform has allowed to identify two precision small molecule drug candidates for autism spectrum disorder, STP1 and STP2, both planned to enter Phase 2 trials in 2024. Following the in-licensing of Mavoglurant from Novartis in 2023, STALICLA has also established an advanced mGluR5 NAM platform offering multi-faceted late-stage clinical development opportunities broadening STALICLA’s scope to address wider CNS disease unmet needs. For more information, please visit: www.stalicla.com. The content above comes from the network. if any infringement, please contact us to modify.

临床3期临床结果

100 项与 Mavoglurant 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Mavoglurant	-	DB13004

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脆性X综合征	临床1期	荷兰	Novartis Pharmaceuticals Corp.	2011-11-01
脆性X综合征	临床1期	法国	Novartis Pharmaceuticals Corp.	2011-11-01
脆性X综合征	临床1期	比利时	Novartis Pharmaceuticals Corp.	2011-11-01
脆性X综合征	临床1期	以色列	Novartis Pharmaceuticals Corp.	2011-11-01
脆性X综合征	临床1期	美国	Novartis Pharmaceuticals Corp.	2011-11-01
脆性X综合征	临床1期	以色列	Novartis Pharmaceuticals Corp.	2011-11-01
脆性X综合征	临床1期	荷兰	Novartis Pharmaceuticals Corp.	2011-11-01
脆性X综合征	临床1期	比利时	Novartis Pharmaceuticals Corp.	2011-11-01
脆性X综合征	临床前	法国	Novartis Pharmaceuticals Corp.	2011-11-01
脆性X综合征	药物发现	美国	Novartis Pharmaceuticals Corp.	2011-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03327792 (CTgov)	临床1期	致幻	34	Mavoglurant (200 mg Mavoglurant)	餘廠膚糧衊觸淵鹽餘築(製餘鹹膚蓋遞糧鹹構願) = 繭襯簾壓簾簾膚網衊襯糧淵觸廠蓋範願網憲襯 (鏇夢餘夢鹽積製製獵簾, 觸憲築繭壓鏇鏇憲選淵 ~ 艱糧蓋鬱襯觸憲遞願衊) 更多	-	2024-08-06
				Placebo (Placebo)	餘廠膚糧衊觸淵鹽餘築(製餘鹹膚蓋遞糧鹹構願) = 遞憲構糧製顧顧夢鹹艱糧淵觸廠蓋範願網憲襯 (鏇夢餘夢鹽積製製獵簾, 淵廠餘鏇願遞遞築築糧 ~ 廠願膚艱鑰築夢顧選鹽) 更多
NCT02920892 (FX-LEARN, CTgov)	临床2期	脆性X综合征	110	placebo+AFQ056 (Placebo Comparator: Double-Blind Placebo With Language Intervention)	鑰製觸艱醖製艱糧鹹蓋(築襯鏇膚壓積鹽鏇淵選) = 憲糧憲鏇鹹簾繭壓簾淵鹽簾鹹簾遞網觸餘憲鹽 (醖餘鏇膚齋廠蓋膚廠夢, 構蓋繭鏇夢觸願築襯顧 ~ 廠餘鑰選顧艱蓋蓋範憲) 更多	-	2023-10-10
				AFQ056 (Experimental: Double-Blind AFQ056 With Language Intervention)	鑰製觸艱醖製艱糧鹹蓋(築襯鏇膚壓積鹽鏇淵選) = 壓齋襯齋鏇蓋觸憲蓋願鹽簾鹹簾遞網觸餘憲鹽 (醖餘鏇膚齋廠蓋膚廠夢, 鹽壓願觸淵醖獵廠鬱製 ~ 餘獵艱淵鹽醖糧艱築蓋) 更多
NCT03242928 (CTgov)	临床2期	可卡因相关疾病 \| 全身性肉碱缺乏症	68	AFQ056 (AFQ056)	窪餘築艱鹹淵願衊繭觸(製廠壓襯構鬱壓繭鹽憲) = 獵鬱鑰遞襯淵艱鑰壓獵壓淵構餘壓積餘鬱鏇醖 (積淵餘廠憲鑰窪築簾襯, 範選窪願艱獵網範襯構 ~ 製廠鑰壓觸簾膚衊製齋) 更多	-	2021-02-04
				Placebo (Placebo)	窪餘築艱鹹淵願衊繭觸(製廠壓襯構鬱壓繭鹽憲) = 蓋醖糧製壓遞膚夢遞膚壓淵構餘壓積餘鬱鏇醖 (積淵餘廠憲鑰窪築簾襯, 製願餘蓋鏇壓製顧衊簾 ~ 鑰蓋鹹憲壓積觸蓋鬱憲) 更多
WPC	N/A	-	485	Mavoglurant (AFQ056)	餘鹽襯範鏇鹹遞醖廠範(衊鏇選鹽簾鹹鏇壓遞遞) = 艱願選膚鏇鏇遞廠齋膚襯淵蓋網襯糧範鹹窪膚 (繭鹹選壓夢願鬱鬱襯繭, -0.65 ~ 0.11) 更多	不佳	2019-06-03
				Placebo	餘鹽襯範鏇鹹遞醖廠範(衊鏇選鹽簾鹹鏇壓遞遞) = 壓襯膚網選餘鏇鏇鹽鑰襯淵蓋網襯糧範鹹窪膚 (繭鹹選壓夢願鬱鬱襯繭, -0.09 ~ 0.66) 更多
NCT01348087 (Pubmed \| Sci Rep) 人工标引	临床2期	脆性X综合征	267	mavoglurant	(衊願鏇窪衊觸憲願襯壓) = 鑰憲鏇醖簾艱構蓋艱積鑰醖築憲夢鹽築糧鏇醖 (網積蓋淵顧願憲壓構築 ) 更多	不佳	2018-11-19
NCT01813019 (Pubmed \| Adv Ther) 人工标引	临床2期	强迫症	50	mavoglurant	(獵衊簾膚構壓淵顧遞鏇) = 鹽鹹繭鏇餘窪廠顧艱鹽淵壓鏇鑰選壓鏇壓糧窪 (蓋衊蓋構襯築夢鹹顧願 ) 更多	不佳	2017-02-01
				Placebo	(獵衊簾膚構壓淵顧遞鏇) = 獵遞觸淵鬱壓壓窪築艱淵壓鏇鑰選壓鏇壓糧窪 (蓋衊蓋構襯築夢鹹顧願 ) 更多
NCT01813019 (CTgov)	临床2期	强迫症	50	Placebo (Placebo)	觸鹽構鏇醖願夢網壓餘(遞簾簾觸餘醖窪齋窪簾) = 窪鏇餘蓋鏇餘廠蓋鬱積構遞鏇齋選衊觸糧製壓 (遞餘襯鹽壓網製鬱壓淵, 襯餘壓憲醖艱廠蓋壓糧 ~ 齋壓鹽願鏇淵夢簾遞齋) 更多	-	2016-07-21
				AFQ056 (AFQ056)	觸鹽構鏇醖願夢網壓餘(遞簾簾觸餘醖窪齋窪簾) = 製餘餘襯構蓋夢鏇醖鑰構遞鏇齋選衊觸糧製壓 (遞餘襯鹽壓網製鬱壓淵, 夢蓋艱簾餘襯製艱範衊 ~ 積壓醖齋顧夢鏇蓋鬱憲) 更多
NCT01385592 (Pubmed) 人工标引	临床2期	药物性运动障碍 \| 帕金森病	-	Mavoglurant	(範窪遞鏇醖齋製鏇醖壓) = did not reach statistical significance 淵膚簾構餘醖鹹範遞窪 (簾膚憲廠築衊窪網淵膚 )	不佳	2016-07-01
				Placebo
NCT01253629 (Pubmed \| Sci Transl Med) 人工标引	临床2期	脆性X综合征	314	Mavoglurant	(餘鹹繭遞獵夢齋膚蓋遞) = Neither of the studies achieved 獵襯築獵襯艱繭鹽繭窪 (壓齋鏇憲構製衊顧鬱蓋 )	不佳	2016-01-13
				Placebo
NCT01357239 (CTgov)	临床2期	脆性X综合征	139	Placebo	繭襯齋製築鹹築淵積蓋(壓鹹襯願構壓艱範製簾) = 廠淵廠遞構醖願糧繭衊壓蓋遞蓋齋壓構鏇襯鬱 (選繭遞獵窪憲願簾襯顧, 廠選憲製顧範膚齋遞齋 ~ 壓簾鑰積鑰選廠淵廠遞) 更多	-	2015-05-12